AU2011332241B2 - Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders - Google Patents

Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders Download PDF

Info

Publication number
AU2011332241B2
AU2011332241B2 AU2011332241A AU2011332241A AU2011332241B2 AU 2011332241 B2 AU2011332241 B2 AU 2011332241B2 AU 2011332241 A AU2011332241 A AU 2011332241A AU 2011332241 A AU2011332241 A AU 2011332241A AU 2011332241 B2 AU2011332241 B2 AU 2011332241B2
Authority
AU
Australia
Prior art keywords
ic3b
lateral flow
complement
flow immunoassay
intact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011332241A
Other languages
English (en)
Other versions
AU2011332241A1 (en
AU2011332241A2 (en
Inventor
Donald Moss
Paul Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KYPHA Inc
Original Assignee
KYPHA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KYPHA Inc filed Critical KYPHA Inc
Publication of AU2011332241A1 publication Critical patent/AU2011332241A1/en
Publication of AU2011332241A2 publication Critical patent/AU2011332241A2/en
Application granted granted Critical
Publication of AU2011332241B2 publication Critical patent/AU2011332241B2/en
Priority to AU2016200772A priority Critical patent/AU2016200772B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
AU2011332241A 2010-11-02 2011-11-02 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders Active AU2011332241B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016200772A AU2016200772B2 (en) 2010-11-02 2016-02-05 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40929710P 2010-11-02 2010-11-02
US61/409,297 2010-11-02
PCT/US2011/058945 WO2012071145A1 (en) 2010-11-02 2011-11-02 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016200772A Division AU2016200772B2 (en) 2010-11-02 2016-02-05 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Publications (3)

Publication Number Publication Date
AU2011332241A1 AU2011332241A1 (en) 2013-05-23
AU2011332241A2 AU2011332241A2 (en) 2013-06-13
AU2011332241B2 true AU2011332241B2 (en) 2015-11-26

Family

ID=46146161

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011332241A Active AU2011332241B2 (en) 2010-11-02 2011-11-02 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
AU2016200772A Active AU2016200772B2 (en) 2010-11-02 2016-02-05 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016200772A Active AU2016200772B2 (en) 2010-11-02 2016-02-05 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Country Status (8)

Country Link
US (2) US9182396B2 (cg-RX-API-DMAC7.html)
EP (2) EP2635702B1 (cg-RX-API-DMAC7.html)
JP (1) JP5859557B2 (cg-RX-API-DMAC7.html)
AU (2) AU2011332241B2 (cg-RX-API-DMAC7.html)
CA (1) CA2816423A1 (cg-RX-API-DMAC7.html)
ES (1) ES2564290T3 (cg-RX-API-DMAC7.html)
MX (1) MX340094B (cg-RX-API-DMAC7.html)
WO (1) WO2012071145A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5859557B2 (ja) * 2010-11-02 2016-02-10 カイファ， インコーポレイテッド 補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法
US8865164B2 (en) * 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
WO2014005138A1 (en) * 2012-06-29 2014-01-03 Kerschensteiner Daniel A Colorimetric gelatinase assay
CN105283761B (zh) * 2013-06-10 2018-02-09 旭化成株式会社 免疫层析诊断试剂盒
CN106461661A (zh) 2014-05-02 2017-02-22 Uab研究基金会 用于诊断和治疗脑膜炎的方法及组合物
WO2017040243A1 (en) * 2015-08-28 2017-03-09 Kypha, Inc. Methods for predicting flare and improving treatment of patients
KR102141591B1 (ko) * 2016-05-13 2020-09-14 광주과학기술원 진단용 키트
EP3775900A1 (en) * 2018-03-26 2021-02-17 Alexion Pharmaceuticals, Inc. High throughput method for measuring the protease activity of complement c3 convertase
EP3581934A1 (en) * 2018-06-14 2019-12-18 Otto-von-Guericke-Universität Magdeburg Complement factors for diagnosis of low-grade infections in a human subject
WO2021222169A1 (en) * 2020-04-27 2021-11-04 Zinselmeyer Bernd H Methods and systems for lateral flow immunoassay of various biological materials including sars-cov2
WO2022067259A1 (en) * 2020-09-28 2022-03-31 Allegheny Singer Research Institute Methods for determining a level of a cell fragment-bound complement activation product
US20240302366A1 (en) * 2021-01-26 2024-09-12 Sekisui Medical Co., Ltd. Immunological assay method
EP4334719A4 (en) * 2021-05-07 2025-04-16 Kypha, Inc. TARGET MEASUREMENT
WO2023192436A1 (en) * 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292700A1 (en) * 2005-06-22 2006-12-28 Naishu Wang Diffused interrupted lateral flow immunoassay device and method

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
JPS595958B2 (ja) 1975-12-30 1984-02-08 トウキヨウケイソウ カブシキガイシヤ 変量測定・伝送装置
DE3366421D1 (en) * 1982-06-14 1986-10-30 Upjohn Co Method and kit for removing and assaying complement system fragments
SE452067B (sv) 1986-04-11 1987-11-09 Ulf R Nilsson Reagens for och sett vid immunkemisk bestemning av c3a
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
IL89790A (en) 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US7371582B2 (en) * 2002-01-23 2008-05-13 Boditechmed Inc. Lateral flow quantitative assay method and strip and laser-induced fluorescence detection device therefor
WO2004093636A2 (en) * 2003-04-17 2004-11-04 Rauno Joks PLASMA C5a LEVELS AS AN INDICATOR OF ASTHMA SEVERITY
KR20060015646A (ko) 2003-06-13 2006-02-17 유니버시티 오브 피츠버그 면역, 혈액 및 염증성 질환의 모니터링 방법
US20070224703A1 (en) 2003-09-29 2007-09-27 Fariba Nayeri Rapid Determination of Hepatocyte Growth Factor (Hgf) in the Body Fluids
WO2005078442A1 (en) 2004-02-10 2005-08-25 Dantini Daniel C Comprehensive food allergy test
WO2006124888A2 (en) * 2005-05-16 2006-11-23 Brendan Bioscience, Llc Detection of antigen specific immunocomplexes
US7910381B2 (en) 2005-10-13 2011-03-22 BioAssay Works Immuno gold lateral flow assay
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
EP2313527A4 (en) * 2008-07-15 2012-11-21 Rapid Pathogen Screening Inc Lateral flow NUCLEIC DETECTOR
WO2010077722A1 (en) * 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis
WO2010135717A2 (en) * 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
JP5859557B2 (ja) 2010-11-02 2016-02-10 カイファ， インコーポレイテッド 補体活性化についての側方流動イムノアッセイおよび補体関連障害のポイント・オブ・ケア評価のための使用法
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292700A1 (en) * 2005-06-22 2006-12-28 Naishu Wang Diffused interrupted lateral flow immunoassay device and method

Also Published As

Publication number Publication date
MX2013004960A (es) 2013-12-16
AU2016200772A1 (en) 2016-02-25
AU2011332241A1 (en) 2013-05-23
ES2564290T3 (es) 2016-03-21
AU2011332241A2 (en) 2013-06-13
MX340094B (es) 2016-06-27
US9939446B2 (en) 2018-04-10
AU2016200772B2 (en) 2018-02-01
US20120141457A1 (en) 2012-06-07
EP3095876A1 (en) 2016-11-23
JP2014502347A (ja) 2014-01-30
EP2635702A1 (en) 2013-09-11
JP5859557B2 (ja) 2016-02-10
US20150346211A1 (en) 2015-12-03
EP2635702A4 (en) 2014-04-02
CA2816423A1 (en) 2012-05-31
US9182396B2 (en) 2015-11-10
EP2635702B1 (en) 2016-02-03
WO2012071145A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
AU2011332241B2 (en) Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
US9164088B2 (en) Detecting complement activation
US20240402195A1 (en) Methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
AU2013256496B2 (en) Detecting complement activation
US10830774B2 (en) Methods and compositions for diagnosis and treatment of meningitis
HK1208267B (en) Detecting complement activation
JP2020139901A (ja) スティーブンス・ジョンソン症候群及び／又は中毒性表皮壊死症の評価方法、評価のためのデータ取得方法、及び評価用キット
HK1234826A1 (en) Methods and compositions for diagnosis and treatment of meningitis
HK1234826B (en) Methods and compositions for diagnosis and treatment of meningitis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 MAY 2013

FGA Letters patent sealed or granted (standard patent)